JP2012025784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012025784A5 JP2012025784A5 JP2011244904A JP2011244904A JP2012025784A5 JP 2012025784 A5 JP2012025784 A5 JP 2012025784A5 JP 2011244904 A JP2011244904 A JP 2011244904A JP 2011244904 A JP2011244904 A JP 2011244904A JP 2012025784 A5 JP2012025784 A5 JP 2012025784A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- culture
- vaccine
- respect
- circovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 13
- 241000700605 Viruses Species 0.000 claims 8
- 238000012360 testing method Methods 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 241000271566 Aves Species 0.000 claims 2
- 241001533384 Circovirus Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000701242 Adenoviridae Species 0.000 claims 1
- 241000701931 Canine parvovirus Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241000700586 Herpesviridae Species 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000202347 Porcine circovirus Species 0.000 claims 1
- 241000702619 Porcine parvovirus Species 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000702247 Reoviridae Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 108700010877 adenoviridae proteins Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000000751 protein extraction Methods 0.000 claims 1
- 238000003908 quality control method Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Claims (9)
- Vero細胞株の培養物中でワクチン抗原を調製するための方法であって、
パルボウイルス、および、サーコウイルスからなる群より選択される病原体に関して試験する工程、
を包含する、方法。 - 前記病原体がイヌパルボウイルス、ブタパルボウイルス、または、ブタサーコウイルスである、請求項1に記載の方法。
- 種ウイルスおよび/または細胞基質および/または培養培地が試験される、請求項1または2に記載の方法。
- 前記方法が、ウイルス培養物を創出するのに使用する物質に関して、ウイルス培養物自体に関して、または、ウイルス培養物から抽出した物質およびこれに派生する物質に関して、実行される、請求項1〜3のいずれか一項に記載の方法。
- 種ウイルスおよび/またはワクチン抗原および/または培養物を、パラインフルエンザウイルス、ヘルペスウイルス科、アデノウイルス科、マイコプラズマ属、トリサーコウイルス、およびトリレオウイルス科からなる群より選択される病原体の存在に関して試験する工程;
を包含する、請求項1〜4のうちのいずれか1項に記載の方法。 - 前記培養物を、免疫化学的検出および/または核酸検出によって試験する、請求項1〜5のうちのいずれか1項に記載の方法。
- 前記検出が、ELISAおよび/またはPCR(RT−PCRを含む)によるものである、請求項6に記載の方法。
- 試験が、以下:
ウイルス感染、増殖段階、ウイルス回収、ウイルス処理、スプリット、表面タンパク質の抽出、ワクチン処方、ワクチンパッケージングの1つの段階で行われる、請求項1〜7のうちのいずれか1項に記載の方法。 - 試験が、通常の品質管理の一部として行われる、請求項1〜8のうちのいずれか1項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04255471 | 2004-09-09 | ||
EP04255471.7 | 2004-09-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011158471A Division JP2011207911A (ja) | 2004-09-09 | 2011-07-19 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013030624A Division JP2013100358A (ja) | 2004-09-09 | 2013-02-20 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012025784A JP2012025784A (ja) | 2012-02-09 |
JP2012025784A5 true JP2012025784A5 (ja) | 2013-03-21 |
Family
ID=35520177
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530801A Withdrawn JP2008512443A (ja) | 2004-09-09 | 2005-09-09 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2011158471A Withdrawn JP2011207911A (ja) | 2004-09-09 | 2011-07-19 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2011244904A Withdrawn JP2012025784A (ja) | 2004-09-09 | 2011-11-08 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2013030624A Withdrawn JP2013100358A (ja) | 2004-09-09 | 2013-02-20 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2015155818A Pending JP2015205929A (ja) | 2004-09-09 | 2015-08-06 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2016230896A Withdrawn JP2017057209A (ja) | 2004-09-09 | 2016-11-29 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2019146040A Pending JP2019210292A (ja) | 2004-09-09 | 2019-08-08 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530801A Withdrawn JP2008512443A (ja) | 2004-09-09 | 2005-09-09 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2011158471A Withdrawn JP2011207911A (ja) | 2004-09-09 | 2011-07-19 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013030624A Withdrawn JP2013100358A (ja) | 2004-09-09 | 2013-02-20 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2015155818A Pending JP2015205929A (ja) | 2004-09-09 | 2015-08-06 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2016230896A Withdrawn JP2017057209A (ja) | 2004-09-09 | 2016-11-29 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
JP2019146040A Pending JP2019210292A (ja) | 2004-09-09 | 2019-08-08 | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
Country Status (16)
Country | Link |
---|---|
US (6) | US8119337B2 (ja) |
EP (5) | EP2179744B1 (ja) |
JP (7) | JP2008512443A (ja) |
AT (2) | ATE488248T1 (ja) |
CA (2) | CA2890962A1 (ja) |
CY (3) | CY1111180T1 (ja) |
DE (3) | DE602005025170D1 (ja) |
DK (4) | DK2578229T3 (ja) |
ES (4) | ES2386272T3 (ja) |
HK (2) | HK1105364A1 (ja) |
HR (4) | HRP20100673T1 (ja) |
PL (4) | PL2236155T3 (ja) |
PT (4) | PT2179744E (ja) |
RS (3) | RS51721B (ja) |
SI (4) | SI2578229T1 (ja) |
WO (1) | WO2006027698A1 (ja) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS51721B (en) * | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Reduction of potential iatrogenic risks associated with influenza vaccines |
ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
PL1951296T5 (pl) | 2005-11-01 | 2015-06-30 | Seqirus Uk Ltd | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem |
AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
BRPI0618254A2 (pt) | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
WO2007052056A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
AU2006310339B2 (en) | 2005-11-04 | 2013-01-10 | Novartis Ag | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
NZ570106A (en) | 2006-01-27 | 2012-04-27 | Novartis Vaccines & Diagnostic | Influenza vaccines containing hemagglutinin and matrix proteins |
JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
CA2647985C (en) | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2497495B3 (en) * | 2006-09-11 | 2021-02-17 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
WO2008059018A2 (en) * | 2006-11-15 | 2008-05-22 | Intervet International B.V. | Vaccine for vaccinating felines and canines against influenza virus |
PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
ES2393162T3 (es) | 2007-06-27 | 2012-12-19 | Novartis Ag | Vacunas antigripales con un contenido reducido de aditivos |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
CA2718430A1 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
CA2741961A1 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
EP2396031A1 (en) | 2009-02-10 | 2011-12-21 | Novartis AG | Influenza vaccines with increased amounts of h3 antigen |
EP3173097A3 (en) | 2009-02-10 | 2017-07-12 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
AU2010212547B2 (en) | 2009-02-10 | 2015-03-12 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
EP2424565A1 (en) | 2009-04-27 | 2012-03-07 | Novartis AG | Adjuvanted vaccines for protecting against influenza |
WO2011030218A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
CN102858961A (zh) * | 2010-05-03 | 2013-01-02 | 葛兰素史密丝克莱恩生物有限公司 | 新方法 |
JP5876036B2 (ja) | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
KR102113512B1 (ko) | 2010-06-01 | 2020-05-22 | 노파르티스 아게 | 동결건조하지 않는 인플루엔자 백신 항원의 농축 |
WO2011151726A2 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
EP2605792B1 (en) | 2010-08-20 | 2014-12-10 | Novartis AG | Soluble needle arrays for delivery of influenza vaccines |
EP2614163B1 (en) | 2010-09-07 | 2016-01-06 | Novartis AG | Generic assays for detection of mammalian reovirus |
ES2572391T3 (es) | 2011-02-25 | 2016-05-31 | Novartis Ag | Control exógeno interno positivo para la detección de virus |
JP2014532620A (ja) | 2011-10-20 | 2014-12-08 | ノバルティス アーゲー | 小児の初回免疫のためのアジュバント添加インフルエンザbウイルスワクチン |
EP3023790A1 (en) * | 2011-12-12 | 2016-05-25 | Novartis AG | Assay for influenza virus hemagglutinins |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
AU2014290203B2 (en) | 2013-07-15 | 2020-12-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
BE1023557B1 (fr) | 2014-02-10 | 2017-05-03 | Univercells Sa | Systeme, appareil et procede pour la production de biomolecules |
RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
KR20230132628A (ko) | 2015-07-07 | 2023-09-15 | 세퀴러스 유케이 리미티드 | 인플루엔자 효능 검정 |
CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
JP2021502350A (ja) | 2017-11-03 | 2021-01-28 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | ジカワクチン及び免疫原性組成物、ならびにその使用方法 |
EP3867412A1 (en) * | 2018-10-15 | 2021-08-25 | REGENXBIO Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
JP2022522112A (ja) | 2019-02-08 | 2022-04-14 | ウィスコンシン アルムニ リサーチ ファンデイション | ヒト化細胞系 |
WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
CN113939311A (zh) | 2019-05-08 | 2022-01-14 | 武田疫苗股份有限公司 | 灭活病毒组合物和寨卡疫苗制剂 |
EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
KR20220128613A (ko) | 2019-11-18 | 2022-09-21 | 세퀴러스 피티와이 리미티드 | 재배열 인플루엔자 바이러스의 제조 방법 |
US11739303B2 (en) * | 2020-01-24 | 2023-08-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized NA |
US20240139306A1 (en) * | 2021-03-01 | 2024-05-02 | Iowa State University Research Foundation, Inc. | Methods and compositions for detecting and producing porcine morbillivirus and vaccines thereof |
CN114107392A (zh) * | 2021-11-22 | 2022-03-01 | 昆明理工大学 | 一种cvb5病毒类病毒样颗粒的制备方法 |
WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4193991A (en) | 1978-12-20 | 1980-03-18 | Cornell Research Foundation, Inc. | Canine parvovirus vaccine |
EP0261955A3 (en) * | 1986-09-26 | 1989-06-07 | E.I. Du Pont De Nemours And Company | Process for immobilization of dna |
US6284492B1 (en) * | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
CA2054228A1 (en) | 1990-10-30 | 1992-05-01 | Masaharu Oki | Muramyldipeptide derivatives and influenza vaccine comprising the derivatives |
JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ3型ウイルス感染症、牛rsウイルス感染症および牛アデノ7型ウイルス感染症5種混合生ワクチン |
IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
EP0684838A1 (en) | 1993-02-19 | 1995-12-06 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
DE4311580C1 (de) * | 1993-04-12 | 1994-08-18 | Werner Prof Dr Med Reutter | Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
CA2415990C (en) | 1994-11-10 | 2009-07-07 | Immuno Aktiengesellschaft | Method for producing biologicals in protein-free culture |
US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
JPH1175833A (ja) * | 1997-06-23 | 1999-03-23 | Chemo Sero Therapeut Res Inst | トリレオウイルスの調製法 |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
DE07008633T1 (de) * | 1997-12-11 | 2008-12-18 | Merial | Virus des multisystemischen Kümmersyndroms bei Absatzferkeln |
GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
CN103540568A (zh) * | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
JP2005532057A (ja) * | 2002-07-09 | 2005-10-27 | バクスター・インターナショナル・インコーポレイテッド | 細胞を培養するための動物性タンパク質非含有培地 |
JP3957188B2 (ja) * | 2002-10-25 | 2007-08-15 | ▲あき▼夫 友田 | 抗ウィルス剤 |
US20040176272A1 (en) | 2003-01-30 | 2004-09-09 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
JP2007525178A (ja) * | 2003-04-25 | 2007-09-06 | メッドイミューン バクシーンズ,インコーポレイティド | メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法 |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
RS51721B (en) * | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Reduction of potential iatrogenic risks associated with influenza vaccines |
RU2519210C2 (ru) | 2007-06-14 | 2014-06-10 | Дзе Борд Оф Риджентс Фор Оклахома Стейт Юниверсити | Вакцины, содержащие генетические варианты парвовируса собак |
-
2005
- 2005-09-09 RS RSP20110075 patent/RS51721B/en unknown
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de active Active
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/en active Active
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es active Active
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en active Application Filing
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/en not_active Revoked
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es active Active
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de active Active
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/en active Active
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es active Active
- 2005-09-09 EP EP05795012A patent/EP1789084B1/en active Active
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es active Active
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 RS RSP20110084 patent/RS51665B/en unknown
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
- 2005-09-09 RS RS20120317A patent/RS52400B/en unknown
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/en not_active Revoked
-
2007
- 2007-11-26 HK HK07112869.6A patent/HK1105364A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 HK HK10109406A patent/HK1144374A1/xx not_active IP Right Cessation
- 2010-12-06 HR HR20100673T patent/HRP20100673T1/hr unknown
-
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
-
2012
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
-
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en active Active
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
-
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
-
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en active Active
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
-
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en active Active
-
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012025784A5 (ja) | ||
HRP20130962T1 (hr) | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva | |
Lei et al. | Severe fever with thrombocytopenia syndrome and its pathogen SFTSV | |
Stöhr et al. | Influenza virus surveillance, vaccine strain selection, and manufacture | |
Kitikoon et al. | Pathogenicity and transmission in pigs of the novel A (H3N2) v influenza virus isolated from humans and characterization of swine H3N2 viruses isolated in 2010-2011 | |
Sridhar et al. | A systematic approach to novel virus discovery in emerging infectious disease outbreaks | |
JP2010537641A5 (ja) | ||
Pawar et al. | Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation | |
Selim et al. | Molecular characterization of full fusion protein (F) of Newcastle disease virus genotype VIId isolated from Egypt during 2012-2016 | |
CN103080304A (zh) | 用于在细胞培养物中生产病毒的过程中除去外来因子的方法 | |
Petiot et al. | Influenza viruses production: evaluation of a novel avian cell line DuckCelt®-T17 | |
ES2895148T3 (es) | Procesos para la producción y purificación de composiciones que contienen ácidos nucleicos | |
WO2006095431A1 (ja) | 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法 | |
Zhang et al. | Isolation of swine influenza virus in cell cultures and embryonated chicken eggs | |
Park et al. | Detection, isolation, and in vitro characterization of porcine parainfluenza virus type 1 isolated from respiratory diagnostic specimens in swine | |
EP2716752A1 (en) | Canine influenza recombinant virus, preparation method therefor and application thereof | |
Zhou et al. | Full-length genomic characterization and molecular evolution of canine parvovirus in China | |
Ma et al. | Identification and characterization of a highly virulent triple reassortant H1N1 swine influenza virus in the United States | |
Liu et al. | Rabbit hepatitis E virus is an opportunistic pathogen in specific-pathogen-free rabbits with the capability of cross-species transmission | |
Umar et al. | Emerging threat of H9N2 viruses in poultry of Pakistan and vaccination strategy | |
Shichinohe et al. | Potency of an inactivated influenza vaccine prepared from a non-pathogenic H5N1 virus against a challenge with antigenically drifted highly pathogenic avian influenza viruses in chickens | |
CN103328629A (zh) | 针对大流行性甲型流感病毒h1n1的新型疫苗 | |
Jia-Yu et al. | Emergence of novel canine parvovirus type 2 and its pathogenesis in raccoon dogs | |
Afzal et al. | Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations | |
Laposova et al. | A simple method for isolation of cell-associated viral particles from cell culture |